56 - Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis and Compensated Liver Cirrhosis in the Open-Label, Long-Term ASSURE Safety Study: Interim Results
Location: Terrace Ballroom 1
Presenting Author: Stuart Gordon, MD – Creighton University School of Medicine
Oral Paper PresentationAnnual Scientific Meeting
8:50 AM – 9:00 AM ET
57 - Monitoring Gaps and Treatment Disparities Among Adults With Chronic Hepatitis B Infection in the United States: Role of Treatment Eligibility Criteria
59 - A Recent Epidemiologic Shift in Herbal and Dietary Supplement-Induced Liver Injury: Two Decades of Experience From the U.S. Drug-Induced Liver Injury Network
Location: Terrace Ballroom 1
Presenting Author: Dina Halegoua-DeMarzio, MD – Sidney Kimmel Medical College at Thomas Jefferson University
Oral Paper PresentationAnnual Scientific Meeting
9:20 AM – 9:30 AM ET
60 - Association of Sodium Glucose Co-Transporter-2 Inhibitors and Serious Liver Events in Patients With Cirrhosis on Diuretics: A Global Cohort Study
61 - Evaluating the Impact of Palliative Care Consultation on 30- and 90-Day Readmissions Among Patients With Decompensated Cirrhosis: A National Perspective
Location: Terrace Ballroom 1
Presenting Author: Aya Akhras, MD – HCA Florida Aventura Hospital and Medical Center
Oral Paper PresentationAnnual Scientific Meeting
9:40 AM – 9:50 AM ET
62 - GLP-1RA and Safety of Gastrointestinal (GI) Endoscopic Procedures A Systematic Review and Meta-Analysis (Late-Breaking Abstract)
Location: Terrace Ballroom 1
Late Breaking Abstract Presenter: Violeta B. Popov, MD, PhD, FACG – NYU Langone Health NY VA Harbor Health System (Manhattan)
Oral Paper PresentationAnnual Scientific Meeting
9:50 AM – 10:00 AM ET
63 - AIM65 as an Indicator of Rebleed and Mortality Risk in Patients Using Factor Xa Inhibitors Hospitalized for a Gastrointestinal (GI) Bleed (Late-Breaking Abstract)
64 - A Randomized, Double-Blind, Placebo Controlled Dose Ranging Study of Auxora in Patients with Acute Pancreatitis (AP) and Accompanying Systemic Inflammatory Response Syndrome (SIRS) - CARPO (NCT04681066) (Late-Breaking Abstract)
Paper Session Moderator: Elizabeth Paine, MD (she/her/hers) – G.V. (Sonny) Montgomery VA Medical Center; University of Mississippi Medical Center
Oral Paper PresentationAnnual Scientific Meeting
8:30 AM – 8:40 AM ET
65 - Fecal Microbiota Transplantation (FMT) With Bezlotoxumab Was Not Better Than FMT Alone in Inflammatory Bowel Disease Patients and Recurrent Clostridioides difficile Infection Results from a Randomized Controlled Trial
68 - Respiratory Syncytial Virus Vaccine is Associated With Better Outcomes in Inflammatory Bowel Disease Patients over 60 Years Old: A US Propensity-Matched Study
Location: Terrace Ballroom 2-3
Presenting Author: Osama Hamid, MD – University of Texas Southwestern Medical Center
Oral Paper PresentationAnnual Scientific Meeting
9:10 AM – 9:20 AM ET
69 - Real World Comparison of Effectiveness, Durability, and Safety of First-Line Advanced Therapies for Ulcerative Proctitis
70 - Efficacy and Safety of Upadacitinib Maintenance Treatment in Patients With Moderately to Severely Active Crohn’s Disease: Two Year Results From the U-ENDURE Long-Term Extension Study
71 - Efficacy of Mirikizumab by Baseline Disease Location in Moderately to Severely Active Crohn’s Disease: Results of the Phase 3 VIVID-1 Study
Location: Terrace Ballroom 2-3
Presenting Author: Edward Barnes, MD, MPH, FACG – University of North Carolina at Chapel Hill School of Medicine
Oral Paper PresentationAnnual Scientific Meeting
9:40 AM – 9:50 AM ET
72 - Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results Through Week 48 From the Phase 3 GRAVITI Study
73 - Week 48 Efficacy Of Guselkumab And Ustekinumab In Crohn’s Disease Based On Prior Response/Exposure To Biologic Therapy: Results From The GALAXI 2 and 3 Phase 3 Studies
74 - TUSCANY-2: A Dose-Ranging Phase IIb Study Evaluating Efficacy and Safety of RO7790121, an Antibody Against Tumor Necrosis Factor-Like Ligand 1A (Anti-TL1A) in Adults With Moderately to Severely Active Ulcerative Colitis
